We are live on
!
Find out more
JC
JBF Capital Portfolio holdings
AUM
$764M
Turnover
38.35%
1-Year Est. Return
24.26%
This Fund
S&P 500
This Quarter
Est. Return
+0.07%
1 Year Est. Return
+24.26%
3 Year Est. Return
+93.63%
5 Year Est. Return
+127.41%
10 Year Est. Return
+469.69%
AUM
$633M
AUM Growth
-$163M
(-20%)
Cap. Flow
-$171M
Cap. Flow
% of AUM
-27.07%
Top 10 Holdings %
Top 10 Hldgs %
87.77%
Holding
108
New
44
Increased
9
Reduced
4
Closed
26
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
1.7
years
Top 20 Avg Time Held Equity + Options
1.2
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
1.7
years
Top 20 Avg Time Held Equity only
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$6.93M |
| 2 |
GE Aerospace
GE
|
+$6.18M |
| 3 |
ACTA
Actua Corp
ACTA
|
+$5.71M |
| 4 |
Kearny Financial
KRNY
|
+$4.73M |
| 5 |
Chord Energy
CHRD
|
+$4.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$223M |
| 2 |
SRUN
Silver Run Acquisition Corporation II Class A
SRUN
|
+$9.46M |
| 3 |
AABA
Altaba Inc
AABA
|
+$4.19M |
| 4 |
QIWI
QIWI PLC
QIWI
|
+$869K |
| 5 |
HTM
U.S. Geothermal Inc.
HTM
|
+$236K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 76.26% |
| 2 | Financials | 6.68% |
| 3 | Technology | 4.79% |
| 4 | Consumer Discretionary | 3.24% |
| 5 | Healthcare | 2.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
PUT
Apple
AAPL
$4.99T
| $1.58M | 0.25% |
+4,000
| New | +$172K |
2018 Q1
0 quarters
|
|
27
Arcus Biosciences
RCUS
$2.91B
| $1.54M | 0.24% |
+100,000
| New | +$1.67M |
2018 Q1
0 quarters
|
|
|
ESTE
28
DELISTED
Earthstone Energy Inc. Class A Common Stock
ESTE
| $1.52M | 0.24% |
150,610
| – | – |
2017 Q4
1 quarter
|
|
29
Mannatech
MTEX
$13.8M
| $1.28M | 0.2% |
81,286
+41,668
| +105% | +$612K |
2017 Q2
3 quarters
|
|
30
Reading International Class A
RDI
$41M
| $1.24M | 0.2% |
74,325
+35,899
| +93% | +$596K |
2017 Q4
1 quarter
|
|
|
GCAP
31
DELISTED
Gain Capital Holdings, Inc.
GCAP
| $1.19M | 0.19% |
176,800
+80,000
| +83% | +$600K |
2017 Q4
1 quarter
|
|
|
AMRWW
32
CALL
DELISTED
Alta Mesa Resources Inc Warrant
AMRWW
| $1.15M | 0.18% |
+740,832
| New | +$1.28M |
2018 Q1
0 quarters
|
|
33
CALL
Tesla
TSLA
$1.43T
| $1.11M | 0.18% |
+4,170
| New | +$91.7K |
2018 Q1
0 quarters
|
|
34
DELISTED
Catalyst Pharmaceutical
CPRX
| $1.1M | 0.17% |
+458,600
| New | +$1.52M |
2018 Q1
0 quarters
|
|
|
FSACU
35
DELISTED
Federal Street Acquisition Corp. Unit
FSACU
| $1.02M | 0.16% |
100,000
| – | – |
2017 Q3
2 quarters
|
|
36
BioMarin Pharmaceuticals
BMRN
$10.8B
| $1.02M | 0.16% |
+12,560
| New | +$1.08M |
2018 Q1
0 quarters
|
|
37
DELISTED
Blueprint Medicines
BPMC
| $992K | 0.16% |
+10,822
| New | +$933K |
2018 Q1
0 quarters
|
|
38
BlueLinx
BXC
$576M
| $909K | 0.14% |
27,900
-3,900
| -12% | -$72.5K |
2017 Q4
1 quarter
|
|
39
iShares MSCI Ireland ETF
EIRL
$76M
| $907K | 0.14% |
19,411
| – | – |
2016 Q1
8 quarters
|
|
|
MR
40
DELISTED
Montage Resources Corporation Common Stock
MR
| $882K | 0.14% |
+40,825
| New | +$1.17M |
2018 Q1
0 quarters
|
|
41
PUT
Amazon
AMZN
$2.75T
| $865K | 0.14% |
+4,000
| New | +$286K |
2018 Q1
0 quarters
|
|
|
JNCE
42
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $852K | 0.13% |
+38,100
| New | +$846K |
2018 Q1
0 quarters
|
|
|
XLNX
43
CALL
DELISTED
Xilinx Inc
XLNX
| $840K | 0.13% |
1,000
| – | – |
2017 Q1
4 quarters
|
|
|
IRL
44
DELISTED
NEW IRELAND FUND INC
IRL
| $724K | 0.11% |
60,100
| – | – |
2016 Q1
8 quarters
|
|
45
Walt Disney
DIS
$191B
| $713K | 0.11% |
+7,100
| New | +$754K |
2018 Q1
0 quarters
|
|
46
CytomX Therapeutics
CTMX
$525M
| $692K | 0.11% |
+24,333
| New | +$695K |
2018 Q1
0 quarters
|
|
47
Genworth Financial
GNW
$3.38B
| $688K | 0.11% |
+242,964
| New | +$730K |
2018 Q1
0 quarters
|
|
48
Bristol-Myers Squibb
BMY
$124B
| $670K | 0.11% |
+10,600
| New | +$682K |
2018 Q1
0 quarters
|
|
49
Central Securities Corp
CET
$1.64B
| $667K | 0.11% |
25,000
| – | – |
2017 Q1
4 quarters
|
|
50
DELISTED
Audentes Therapeutics, Inc
BOLD
| $640K | 0.1% |
+21,300
| New | +$721K |
2018 Q1
0 quarters
|
|
Similar funds
UCMOK
EIM
CAAM
KLI
CT
ANRF
NI
HI
JBF Capital's Q1 2018 Portfolio in Review
As of Q1 2018, JBF Capital held 108 positions worth $633M, down 20% from $795M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
JBF Capital withdrew a net $171M in Q1 2018, closing 26 positions and reducing 4 holdings. Its most notable exit was Silver Run Acquisition Corporation II Class A, an estimated $9.46M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 76% of assets, down from 87% a quarter earlier, followed by Financials and Technology.
Against the trend, JBF Capital opened a new position in Alexion Pharmaceuticals worth $6.46M.
- JBF Capital's largest Q1 2018 buy was Alexion Pharmaceuticals: 58,000 shares worth $6.46M.
- JBF Capital added most to Chord Energy in Q1 2018, an estimated $4.49M increase.
- JBF Capital's biggest Q1 2018 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $223M.
- JBF Capital fully exited Silver Run Acquisition Corporation II Class A in Q1 2018, selling an estimated $9.46M.
- JBF Capital's ten largest holdings make up 88% of its $633M portfolio in Q1 2018.
- JBF Capital opened 44 new positions and closed 26 in Q1 2018.
- JBF Capital's portfolio value fell 20% quarter-over-quarter to $633M.
Based on JBF Capital's 13F filing for Q1 2018, filed 11 May 2018.